T&K: Wholly-owned subsidiary receives drug registration certificate for Alendronate Sodium Tablets
T&K announced that its wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. recently received the "Drug Registration Certificate" for Alendronate Sodium Tablets issued by the National Medical Products Administration. Alendronate Sodium Tablets are indicated for the treatment of osteoporosis to prevent hip and spinal fractures, as well as for the treatment of glucocorticoid-induced osteoporosis, among others. A total of 24 companies in China have obtained the drug registration approval for this medication
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments